Literature DB >> 29217697

T-PLL: another check on the venetoclax list?

Prithviraj Bose1, Marina Y Konopleva1.   

Abstract

Mesh:

Substances:

Year:  2017        PMID: 29217697      PMCID: PMC5721286          DOI: 10.1182/blood-2017-10-809673

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

Review 1.  Pathways and mechanisms of venetoclax resistance.

Authors:  Prithviraj Bose; Varsha Gandhi; Marina Konopleva
Journal:  Leuk Lymphoma       Date:  2017-01-31

2.  Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Authors:  E I Andersson; S Pützer; B Yadav; O Dufva; S Khan; L He; L Sellner; A Schrader; G Crispatzu; M Oleś; H Zhang; S Adnan-Awad; S Lagström; D Bellanger; J P Mpindi; S Eldfors; T Pemovska; P Pietarinen; A Lauhio; K Tomska; C Cuesta-Mateos; E Faber; S Koschmieder; T H Brümmendorf; S Kytölä; E-R Savolainen; T Siitonen; P Ellonen; O Kallioniemi; K Wennerberg; W Ding; M-H Stern; W Huber; S Anders; J Tang; T Aittokallio; T Zenz; M Herling; S Mustjoki
Journal:  Leukemia       Date:  2017-08-14       Impact factor: 11.528

Review 3.  T-cell Prolymphocytic Leukemia.

Authors:  Amit Sud; Claire Dearden
Journal:  Hematol Oncol Clin North Am       Date:  2017-04       Impact factor: 3.722

4.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.

Authors:  Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

Review 5.  Targeting BCL-2 in B-cell lymphomas.

Authors:  Matthew S Davids
Journal:  Blood       Date:  2017-07-19       Impact factor: 22.113

6.  Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.

Authors:  Marina Konopleva; Daniel A Pollyea; Jalaja Potluri; Brenda Chyla; Leah Hogdal; Todd Busman; Evelyn McKeegan; Ahmed Hamed Salem; Ming Zhu; Justin L Ricker; William Blum; Courtney D DiNardo; Tapan Kadia; Martin Dunbar; Rachel Kirby; Nancy Falotico; Joel Leverson; Rod Humerickhouse; Mack Mabry; Richard Stone; Hagop Kantarjian; Anthony Letai
Journal:  Cancer Discov       Date:  2016-08-12       Impact factor: 39.397

7.  Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199.

Authors:  Triona Ni Chonghaile; Justine E Roderick; Cian Glenfield; Jeremy Ryan; Stephen E Sallan; Lewis B Silverman; Mignon L Loh; Stephen P Hunger; Brent Wood; Daniel J DeAngelo; Richard Stone; Marian Harris; Alejandro Gutierrez; Michelle A Kelliher; Anthony Letai
Journal:  Cancer Discov       Date:  2014-07-03       Impact factor: 39.397

8.  Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.

Authors:  Seong Lin Khaw; Santi Suryani; Kathryn Evans; Jennifer Richmond; Alissa Robbins; Raushan T Kurmasheva; Catherine A Billups; Stephen W Erickson; Yuelong Guo; Peter J Houghton; Malcolm A Smith; Hernan Carol; Andrew W Roberts; David C S Huang; Richard B Lock
Journal:  Blood       Date:  2016-06-24       Impact factor: 22.113

9.  Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia.

Authors:  Mark J Kiel; Thirunavukkarasu Velusamy; Delphine Rolland; Anagh A Sahasrabuddhe; Fuzon Chung; Nathanael G Bailey; Alexandra Schrader; Bo Li; Jun Z Li; Ayse B Ozel; Bryan L Betz; Roberto N Miranda; L Jeffrey Medeiros; Lili Zhao; Marco Herling; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  Blood       Date:  2014-05-13       Impact factor: 22.113

10.  First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.

Authors:  Bernd Boidol; Christoph Kornauth; Emiel van der Kouwe; Nicole Prutsch; Lukas Kazianka; Sinan Gültekin; Gregor Hoermann; Marius E Mayerhoefer; Georg Hopfinger; Alexander Hauswirth; Michael Panny; Marie-Bernadette Aretin; Bernadette Hilgarth; Wolfgang R Sperr; Peter Valent; Ingrid Simonitsch-Klupp; Richard Moriggl; Olaf Merkel; Lukas Kenner; Ulrich Jäger; Stefan Kubicek; Philipp B Staber
Journal:  Blood       Date:  2017-09-27       Impact factor: 22.113

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.